KF4939, a new anti-platelet agent, inhibits activation of phospholipase C and A2 in rabbit platelets.
Effect of KF4939 on activation of phospholipase C and A2 was examined by using rabbit platelets prelabelled with [14C]-arachidonic acid. The results showed that KF4939 inhibited the activation of the two phospholipases, separately. The inhibition of phospholipase C activation is thought to be a possible mechanism of KF4939 to inhibit aggregation and secretion which are independent of the synthesis of cyclooxygenase products such as thromboxane A2.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood; D001549:Benzamides / Q000494:pharmacology*; D001792:Blood Platelets / Q000201:enzymology*; D000001:Calcimycin / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D066298:In Vitro Techniques; D010712:Phosphatidic Acids / Q000097:blood; D010740:Phospholipases / Q000097:blood*; D010741:Phospholipases A / Q000097:blood*; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D012701:Serotonin / Q000097:blood; D010738:Type C Phospholipases / Q000097:blood*
D000959:Antihypertensive Agents; D001095:Arachidonic Acids; D001549:Benzamides; D010712:Phosphatidic Acids; D016718:Arachidonic Acid; D012701:Serotonin; D000001:Calcimycin; C037861:2,2'-dithiobis(N-2-hydroxypropylbenzamide); D010740:Phospholipases; D010741:Phospholipases A; D010738:Type C Phospholipases